Toward managing chronic rejection after lung transplant: The fate and effects of inhaled cyclosporine in a complex environment

Advanced Drug Delivery Reviews

Volumn 63, Issue 1-2, 2011, Pages 88-109

  Niven, Ralph W ^a  

^a APT Pharmaceuticals ^*  (United States)

Author keywords

Aerosol; Chronic rejection; Cyclosporine A; Immunology; Inhalation; Lung transplantation; Pharmacokinetics

Indexed keywords

ANTI-INFLAMMATORY EFFECTS; CELL TYPES; CHRONIC REJECTION; COMPLEX ENVIRONMENTS; CYCLOSPORINE A; EFFECTIVE CONCENTRATION; INHALATION; LUNG SURFACE; LUNG TRANSPLANT; LUNG TRANSPLANTATION; MICROENVIRONMENTS; PHARMACOKINETICS AND PHARMACODYNAMICS; POTENTIAL EFFECTS; T CELLS;

ATMOSPHERIC AEROSOLS; IMMUNOLOGY; PHARMACOKINETICS;

BIOLOGICAL ORGANS;

BASILIXIMAB; CALCINEURIN; CYCLOPHILIN; CYCLOSPORIN A; GLUTATHIONE DISULFIDE; LIPOSOME; LUNG SURFACTANT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROPYLENE GLYCOL; TRANSCRIPTION FACTOR FOXP3;

AEROSOL; AREA UNDER THE CURVE; B LYMPHOCYTE; BASEMENT MEMBRANE; BASOPHIL; BLOOD; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; CILIATED EPITHELIUM; CLARA CELL; DENDRITIC CELL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; EOSINOPHIL; FORCED EXPIRATORY VOLUME; GOBLET CELL; HUMAN; LUNG ALVEOLUS CELL TYPE 1; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS MACROPHAGE; LUNG ENDOTHELIUM; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG GRAFT REJECTION; LUNG INTERSTITIUM; LUNG LYMPH; LUNG TRANSPLANTATION; MAST CELL; MOLECULAR WEIGHT; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TIGHT JUNCTION;

ADMINISTRATION, INHALATION; ANIMALS; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION;

EID: 79953026762     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.10.004     Document Type: Review

References (406)

1. Al-Githmi I., Batawil N., Shigemura N., Hsin M., Lee T.W., He G.W., Yim A. Bronchiolitis obliterans following lung transplantation. Eur. J. Cardiothorac. Surg. 2006, 30:846-851.
2. Boehler A., Estenne M. Post-transplant bronchiolitis obliterans. Eur. Respir. J. 2003, 22:1007-1018.
3. Belperio J.A., Weigt S.S., Fishbein M.C., Lynch J.P. Chronic lung allograft rejection: mechanisms and therapy. Proc. Am. Thorac. Soc. 2009, 6:108-121.
4. Smith-Seiler D.A., Iacono A.T. Obliterative bronchiolitis in the lung transplant recipient. A powerful foe. Adv. Nurse Pract. 2004, 12:69-74.
5. Weigt S.S., Wallace W.D., Derhovanessian A., Saggar R., Saggar R., Lynch J.P., Belperio J.A. Chronic allograft rejection: epidemiology, diagnosis, pathogenesis, and treatment. Semin Respir Crit Care Med 2010, 31:189-207.
6. Shilling R.A., Wilkes D.S. Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond. Am. J. Transplant. 2009, 9:1714-1718.
7. Orens J.B., Garrity E.R. General overview of lung transplantation and review of organ allocation. Proc. Am. Thorac. Soc. 2009, 6:13-19.
8. Zijlstra G.S., Wolting J., Prop J., Petersen A.H., Hinrichs W.L., Uges D.R., Kerstjens H.A., van der Bij W., Frijlink H.W. Efficacy of a new pulmonary cyclosporine a powder formulation for prevention of transplant rejection in rats. J. Heart Lung Transplant. 2009, 28:486-492.
9. Letsou G.V., Safi H.J., Reardon M.J., Ergenoglu M., Li Z., Klonaris C.N., Baldwin J.C., Gilbert B.E., Waldrep J.C. Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann. Thorac. Surg. 1999, 68:2044-2048.
10. Gilbert B.E., Knight C., Alvarez F.G., Waldrep C., Rodarte J.R., Knight V., Eschenbacher W.L. Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am. J. Respir. Crit. Care Med. 1997, 156:1789-1793.
11. Behr J., Zimmermann G., Baumgartner R., Leuchte H., Neurohr C., Brand P., Herpich C., Sommerer K., Seitz J., Menges G., Tillmanns S., Keller M. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J. Aerosol Med. Pulm. Drug Deliv. 2009, 22:1-9.
12. Keenan R.J., Duncan A.J., Yousem S.A., Zenati M., Schaper M., Dowling R.D., Alarie Y., Burckart G.J., Griffith B.P. Improved immunosuppression with aerosolized cyclosporine in experimental pulmonary transplantation. Transplantation 1992, 53:20-25.
13. O'Riordan T.G., Iacono A., Keenan R.J., Duncan S.R., Burckart G.J., Griffith B.P., Smaldone G.C. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am. J. Respir. Crit. Care Med. 1995, 151:516-521.
14. Iacono A.T., Smaldone G.C., Keenan R.J., Diot P., Dauber J.H., Zeevi A., Burckart G.J., Griffith B.P. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am. J. Respir. Crit. Care Med. 1997, 155:1690-1698.
15. Keenan R.J., Iacono A., Dauber J.H., Zeevi A., Yousem S.A., Ohori N.P., Burckart G.J., Kawai A., Smaldone G.C., Griffith B.P. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J. Thorac. Cardiovasc. Surg. 1997, 113:335-340. discussion 340-331.
16. Mitruka S.N., Pham S.M., Zeevi A., Li S., Cai J., Burckart G.J., Yousem S.A., Keenan R.J., Griffith B.P. Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation. J. Thorac. Cardiovasc. Surg. 1998, 115:28-36. discussion 36-27.
17. Corcoran T.E. Inhaled delivery of aerosolized cyclosporine. Adv. Drug Deliv. Rev. 2006, 58:1119-1127.
18. Propylene glycol. Handbook of Pharmaceutical Excipients 2003, 521. Pharmaceutical Press and the American Pharmaceutical Association, Chicago. R.C. Row, P.J. Shskey, P.J. Weller (Eds.).
19. Higenbottam T., Jackson M., Woolman P., Lowry R., Wallwork J. The cough response to ultrasonically nebulized distilled water in heart-lung transplantation patients. Am. Rev. Respir. Dis. 1989, 140:58-61.
20. Smaldone G.C. Deposition patterns of nebulized drugs: is the pattern important?. J. Aerosol Med. 1994, 7:S25-S32.
21. Martinu T., Chen D.F., Palmer S.M. Acute rejection and humoral sensitization in lung transplant recipients. Proc. Am. Thorac. Soc. 2009, 6:54-65.
22. Fishman J.A. Infection in solid-organ transplant recipients. N Engl J. Med. 2007, 357:2601-2614.
23. Munro P.E., Holland A.E., Bailey M., Button B.M., Snell G.I. Pulmonary rehabilitation following lung transplantation. Transplant. Proc. 2009, 41:292-295.
24. Herve P., Silbert D., Cerrina J., Simonneau G., Dartevelle P. Impairment of bronchial mucociliary clearance in long-term survivors of heart/lung and double-lung transplantation. The Paris-Sud Lung Transplant Group. Chest 1993, 103:59-63.
25. Lefevbre A. Atomization and sprays 1988, Taylor and Francis. 1 ed.
26. Burckart G.J., Smaldone G.C., Eldon M.A., Venkataramanan R., Dauber J., Zeevi A., McCurry K., McKaveney T.P., Corcoran T.E., Griffith B.P., Iacono A.T. Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharm. Res. 2003, 20:252-256.
27. Goldstein D.A., Solomon A.K. Determination of equivalent pore radius for human red cells by osmotic pressure measurement. J. Gen. Physiol. 1960, 44:1-17.
28. Watson C.J., Rowland M., Warhurst G. Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am. J. Physiol. Cell Physiol. 2001, 281:C388-C397.
29. Venitz J. Qualifying excipients for inhaled dosage forms - toxicological essentials for the United States and Europe. Respiratory Drug Delivery - Europe 2005 2005, 53-63. Virginia Commonwealth University, Paris. R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman (Eds.).
30. Niven R.W., Corcoran T. Impact of pharmacokinetics on the anticipated duration of calcineurin inhibition after inhalation of cyclosporine solution. J. Heart Lung Transplant. 2010, 29:S140.
31. Rohatagi S., Calic F., Harding N., Ozoux M.L., Bouriot J.P., Kirkesseli S., DeLeij L., Jensen B.K. Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients. J. Clin. Pharmacol. 2000, 40:1211-1226.
32. Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther. Drug Monit. 1991, 13:465-477.
33. Fahr A. Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 1993, 24:472-495.
34. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6:67-74.
35. Dobbs L.G., Johnson M.D. Alveolar epithelial transport in the adult lung. Respir. Physiol. Neurobiol. 2007, 159:283-300.
36. Schanker L.S., Hemberger J.A. Relation between molecular weight and pulmonary absorption rate of lipid-insoluble compounds in neonatal and adult rats. Biochem. Pharmacol. 1983, 32:2599-2601.
37. Brown R.A., Schanker L.S. Absorption of aerosolized drugs from the rat lung. Drug Metab. Dispos. 1983, 11:355-360.
38. Ismailos G., Reppas C., Dressman J.B., Macheras P. Unusual solubility behaviour of cyclosporin A in aqueous media. J. Pharm. Pharmacol. 1991, 43:287-289.
39. el Tayar N., Mark A.E., Vallat P., Brunne R.M., Testa B., van Gunsteren W.F. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J. Med. Chem. 1993, 36:3757-3764.
40. Taljanski W., Pierzynowski S.G., Lundin P.D., Westrom B.R., Eirefelt S., Podlesny J., Dahlback M., Siwinska-Golebiowska H., Karlsson B.W. Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats. Drug Metab. Dispos. 1997, 25:917-920.
41. Crapo J.D., Barry B.E., Gehr P., Bachofen M., Weibel E.R. Cell number and cell characteristics of the normal human lung. Am. Rev. Respir. Dis. 1982, 126:332-337.
42. Bastacky J., Lee C.Y., Goerke J., Koushafar H., Yager D., Kenaga L., Speed T.P., Chen Y., Clements J.A. Alveolar lining layer is thin and continuous: low-temperature scanning electron microscopy of rat lung. J. Appl. Physiol. 1995, 79:1615-1628.
43. Veldhuizen R., Possmayer F. Phospholipid metabolism in lung surfactant. Subcell. Biochem. 2004, 37:359-388.
44. Bachofen H., Schurch S. Alveolar surface forces and lung architecture. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2001, 129:183-193.
45. Scarpelli E.M. Physiology of the alveolar surface network. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2003, 135:39-104.
46. Notter R.H. Analyses of surfactant activity and its contribution to lung mechanics and stability. Lung Surfactants: Basic Science and Clinical Applications 2000, 151-169. Marcel Dekker, New York.
47. Perez-Gil J. Lipid-protein interactions of hydrophobic proteins SP-B and SP-C in lung surfactant assembly and dynamics. Pediatr. Pathol. Mol. Med. 2001, 20:445-469.
48. Weaver T.E., Conkright J.J. Function of surfactant proteins B and C. Annu. Rev. Physiol. 2001, 63:555-578.
49. Wright J.R. Immunoregulatory functions of surfactant proteins. Nat. Rev. Immunol. 2005, 5:58-68.
50. Kuroki Y., Takahashi M., Nishitani C. Pulmonary collectins in innate immunity of the lung. Cell. Microbiol. 2007, 9:1871-1879.
51. Serrano A.G., Perez-Gil J. Protein-lipid interactions and surface activity in the pulmonary surfactant system. Chem. Phys. Lipids 2006, 141:105-118.
52. Ouyang C., Choice E., Holland J., Meloche M., Madden T.D. Liposomal cyclosporine. Characterization of drug incorporation and interbilayer exchange. Transplantation 1995, 60:999-1006.
53. Gommers D., Haitsma J.J., Lachmann B. Surfactant as a carrier: influence of immunosuppressive agents on surfactant activity. Clin. Physiol. Funct. Imaging 2006, 26:357-361.
54. Walther F.J., Gordon L.M., Zasadzinski J.A., Sherman M.A., Waring A.J. Surfactant protein B and C analogues. Mol. Genet. Metab. 2000, 71:342-351.
55. van 't Veen A., Gommers D., Mouton J.W., Kluytmans J.A., Krijt E.J., Lachmann B. Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity. Br. J. Pharmacol. 1996, 118:593-598.
56. Haitsma J.J., Lachmann U., Lachmann B. Exogenous surfactant as a drug delivery agent. Adv. Drug Deliv. Rev. 2001, 47:197-207.
57. Fahr A., Seelig J. Liposomal formulations of cyclosporin A: a biophysical approach to pharmacokinetics and pharmacodynamics. Crit. Rev. Ther. Drug Carrier Syst. 2001, 18:141-172.
58. Muller R.H., Runge S.A., Ravelli V., Thunemann A.F., Mehnert W., Souto E.B. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 2008, 68:535-544.
59. Wasan K.M., Pritchard P.H., Ramaswamy M., Wong W., Donnachie E.M., Brunner L.J. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm. Res. 1997, 14:1613-1620.
60. Kwong M., Sivak O., Kwong E.H., Wasan K.M. Cyclosporine A transfer between high- and low-density lipoproteins: independent from lipid transfer protein I-facilitated transfer of lipoprotein-coated phospholipids because of high affinity of cyclosporine a for the protein component of lipoproteins. J. Pharm. Sci. 2001, 90:1308-1317.
61. Lemaire M., Tillement J.P. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J. Pharm. Pharmacol. 1982, 34:715-718.
62. Lautz J., Kessler H., van Gunsteren W.F., Weber H.P., Wenger R.M. On the dependence of molecular conformation on the type of solvent environment: a molecular dynamics study of cyclosporin A. Biopolymers 1990, 29:1669-1687.
63. Endres R.G., Wingreen N.S. Accuracy of direct gradient sensing by single cells. Proc. Natl. Acad. Sci. USA 2008, 105:15749-15754.
64. Bagorda A., Parent C.A. Eukaryotic chemotaxis at a glance. J. Cell Sci. 2008, 121:2621-2624.
65. Gomez-Mouton C., Manes S. Establishment and maintenance of cell polarity during leukocyte chemotaxis. Cell Adh. Migr. 2007, 1:69-76.
66. Damsker J.M., Bukrinsky M.I., Constant S.L. Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J. Leukoc. Biol. 2007, 82:613-618.
67. Sabnis A.S., Shadid M., Yost G.S., Reilly C.A. Human lung epithelial cells express a functional cold-sensing TRPM8 variant. Am. J. Respir. Cell Mol. Biol. 2008, 39:466-474.
68. White C.R., Frangos J.A. The shear stress of it all: the cell membrane and mechanochemical transduction. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2007, 362:1459-1467.
69. Janmey P.A., McCulloch C.A. Cell mechanics: integrating cell responses to mechanical stimuli. Annu. Rev. Biomed. Eng. 2007, 9:1-34.
70. Homolya L., Steinberg T.H., Boucher R.C. Cell to cell communication in response to mechanical stress via bilateral release of ATP and UTP in polarized epithelia. J. Cell Biol. 2000, 150:1349-1360.
71. Arora K., Gwinn W.M., Bower M.A., Watson A., Okwumabua I., MacDonald H.R., Bukrinsky M.I., Constant S.L. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J. Immunol. 2005, 175:517-522.
72. Linton K.J. Structure and function of ABC transporters. Physiology (Bethesda) 2007, 22:122-130.
73. Rees D.C., Johnson E., Lewinson O. ABC transporters: the power to change. Nat. Rev. Mol. Cell Biol. 2009, 10:218-227.
74. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 2003, 55:3-29.
75. Taylor P., Husi H., Kontopidis G., Walkinshaw M.D. Structures of cyclophilin-ligand complexes. Prog. Biophys. Mol. Biol. 1997, 67:155-181.
76. Huai Q., Kim H.Y., Liu Y., Zhao Y., Mondragon A., Liu J.O., Ke H. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12037-12042.
77. Harding M.W., Handschumacher R.E. Cyclophilin, a primary molecular target for cyclosporine. Structural and functional implications. Transplantation 1988, 46:29S-35S.
78. Tuma P.L., Hubbard A.L. Transcytosis: crossing cellular barriers. Physiol. Rev. 2003, 83:871-932.
79. Chung N.S., Wasan K.M. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv. Drug Deliv. Rev. 2004, 56:1315-1334.
80. Dunina-Barkovskaya A. Tight junctions: facts and models. Membr. Cell Biol. 1998, 11:555-589.
81. Schneeberger E.E., Lynch R.D. The tight junction: a multifunctional complex. Am. J. Physiol. Cell Physiol. 2004, 286:C1213-C1228.
82. Vreim C.E., Snashall P.D., Staub N.C. Protein composition of lung fluids in anesthetized dogs with acute cardiogenic edema. Am. J. Physiol. 1976, 231:1466-1469.
83. Hastings R.H., Folkesson H.G., Matthay M.A. Mechanisms of alveolar protein clearance in the intact lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L679-L689.
84. Coyne C.B., Vanhook M.K., Gambling T.M., Carson J.L., Boucher R.C., Johnson L.G. Regulation of airway tight junctions by proinflammatory cytokines. Mol. Biol. Cell 2002, 13:3218-3234.
85. Conforti E., Fenoglio C., Bernocchi G., Bruschi O., Miserocchi G.A. Morpho-functional analysis of lung tissue in mild interstitial edema. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 282:L766-L774.
86. Timpl R., Aumailley M. Biochemistry of basement membranes. Adv. Nephrol. Necker Hosp. 1989, 18:59-76.
87. Leblond C.P., Inoue S. Structure, composition, and assembly of basement membrane. Am. J. Anat. 1989, 185:367-390.
88. Inoue S. Basic structure of basement membranes is a fine network of "cords," irregular anastomosing strands. Microsc. Res. Tech. 1994, 28:29-47.
89. Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit. Rev. Biochem. Mol. Biol. 1992, 27:93-127.
90. Furuyama A., Kimata K., Mochitate K. Assembly of basement membrane in vitro by cooperation between alveolar epithelial cells and pulmonary fibroblasts. Cell Struct. Funct. 1997, 22:603-614.
91. Tzu J., Marinkovich M.P. Bridging structure with function: structural, regulatory, and developmental role of laminins. Int. J. Biochem. Cell Biol. 2008, 40:199-214.
92. Sasaki T., Fassler R., Hohenester E. Laminin: the crux of basement membrane assembly. J. Cell Biol. 2004, 164:959-963.
93. Ward C., De Soyza A., Fisher A.J., Pritchard G., Forrest I., Corris P. A descriptive study of small airway reticular basement membrane thickening in clinically stable lung transplant recipients. J. Heart Lung Transplant. 2005, 24:533-537.
94. Law L., Zheng L., Orsida B., Levvey B., Oto T., Kotsimbos A.T., Snell G.I., Williams T.J. Early changes in basement membrane thickness in airway walls post-lung transplantation. J. Heart Lung Transplant. 2005, 24:1571-1576.
95. Negrini D., Passi A. Interstitial matrix and transendothelial fluxes in normal lung. Respir. Physiol. Neurobiol. 2007, 159:301-310.
96. Davidson J.M. Biochemistry and turnover of lung interstitium. Eur. Respir. J. 1990, 3:1048-1063.
97. Korpos E., Wu C., Sorokin L. Multiple roles of the extracellular matrix in inflammation. Curr. Pharm. Des. 2009, 15:1349-1357.
98. Chan M.W., Arora P.D., McCulloch C.A. Cyclosporin inhibition of collagen remodeling is mediated by gelsolin. Am. J. Physiol. Cell Physiol. 2007, 293:C1049-C1058.
99. Aukland K., Reed R.K. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol. Rev. 1993, 73:1-78.
100. Hedenstierna G., Lattuada M. Lymphatics and lymph in acute lung injury. Curr. Opin. Crit. Care 2008, 14:31-36.
101. Skandalakis J.E., Skandalakis L.J., Skandalakis P.N. Anatomy of the lymphatics. Surg. Oncol. Clin. N. Am. 2007, 16:1-16.
102. Taylor A.E. Capillary fluid filtration. Starling forces and lymph flow. Circ. Res. 1981, 49:557-575.
103. Aharinejad S., Bock P., Firbas W., Schraufnagel D.E. Pulmonary lymphatics and their spatial relationship to venous sphincters. Anat. Rec. 1995, 242:531-544.
104. Pepper M.S., Skobe M. Lymphatic endothelium: morphological, molecular and functional properties. J. Cell Biol. 2003, 163:209-213.
105. Ruggiero R., Fietsam R., Thomas G.A., Muz J., Farris R.H., Kowal T.A., Myles J.L., Stephenson L.W., Baciewicz F.A. Detection of canine allograft lung rejection by pulmonary lymphoscintigraphy. J. Thorac. Cardiovasc. Surg. 1994, 108:253-258.
106. Ruggiero R., Muz J., Fietsam R., Thomas G.A., Welsh R.J., Miller J.E., Stephenson L.W., Baciewicz F.A. Reestablishment of lymphatic drainage after canine lung transplantation. J. Thorac. Cardiovasc. Surg. 1993, 106:167-171.
107. Kim J., Chung K.H., Lee C.M., Seo Y.S., Song H.C., Lee K.Y. Lymphatic delivery of 99mTc-labeled dextran acetate particles including cyclosporine A. J. Microbiol. Biotechnol. 2008, 18:1599-1605.
108. El-Chemaly S., Levine S.J., Moss J. Lymphatics in lung disease. Ann. NY Acad. Sci. 2008, 1131:195-202.
109. Hainis K.D., Sznajder J.I., Schraufnagel D.E. Lung lymphatics cast from the airspace. Am. J. Physiol. 1994, 267:L199-L205.
110. Pries A.R., Kuebler W.M. Normal endothelium. Handb. Exp. Pharmacol. 2006, 1-40.
111. Stewart S., Fishbein M.C., Snell G.I., Berry G.J., Boehler A., Burke M.M., Glanville A., Gould F.K., Magro C., Marboe C.C., McNeil K.D., Reed E.F., Reinsmoen N.L., Scott J.P., Studer S.M., Tazelaar H.D., Wallwork J.L., Westall G., Zamora M.R., Zeevi A., Yousem S.A. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J. Heart Lung Transplant. 2007, 26:1229-1242.
112. Batiuk T.D., Pazderka F., Enns J., De Castro L., Halloran P.F. Cyclosporine inhibition of leukocyte calcineurin is much less in whole blood than in culture medium. Transplantation 1996, 61:158-161.
113. Fels A.O., Cohn Z.A. The alveolar macrophage. J. Appl. Physiol. 1986, 60:353-369.
114. du Bois R.M. The alveolar macrophage. Thorax 1985, 40:321-327.
115. Bowden D.H. The alveolar macrophage. Environ. Health Perspect. 1984, 55:327-341.
116. Alexis N.E., Lay J.C., Zeman K.L., Geiser M., Kapp N., Bennett W.D. In vivo particle uptake by airway macrophages in healthy volunteers. Am. J. Respir. Cell Mol. Biol. 2006, 34:305-313.
117. Poelma D.L., Ju M.R., Bakker S.C., Zimmermann L.J., Lachmann B.F., van Iwaarden J.F. A common pathway for the uptake of surfactant lipids by alveolar cells. Am. J. Respir. Cell Mol. Biol. 2004, 30:751-758.
118. Poelma D.L., Zimmermann L.J., Scholten H.H., Lachmann B., van Iwaarden J.F. In vivo and in vitro uptake of surfactant lipids by alveolar type II cells and macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 283:L648-L654.
119. Fung J.J., Zeevi A., Kaufman C., Paradis I.L., Dauber J.H., Hardesty R.L., Griffith B., Duquesnoy R.J. Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum. Immunol. 1985, 14:287-294.
120. Maye I., de Fraissinette A., Cruz-Orive L.M., Vonderscher J., Richter F., Gehr P. Comparison of the rate of phagocytosis of orthorhombic cyclosporine A (CsA) and latex particles by alveolar macrophages from hamsters. Cell. Mol. Life Sci. 1997, 53:689-696.
121. Maye I., de Fraissinette A., Cruz-Orive L.M., Andersen E., Niederlander C., Bueb W., Froehlich C., Schreier M., Vonderscher J., Richter F., Cordier A., Gehr P. Comparison of the phagocytosis of two types of cyclosporin (SDZ OXL 400 and SDZ IMM 125) by alveolar macrophages from hamsters. Cell Biol. Toxicol. 1998, 14:411-418.
122. Hukkanen J., Pelkonen O., Hakkola J., Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit. Rev. Toxicol. 2002, 32:391-411.
123. Castell J.V., Donato M.T., Gomez-Lechon M.J. Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach. Exp. Toxicol. Pathol. 2005, 57(Suppl 1):189-204.
124. Sato M., Keshavjee S. Bronchiolitis obliterans syndrome: alloimmune-dependent and -independent injury with aberrant tissue remodeling. Semin. Thorac. Cardiovasc. Surg. 2008, 20:173-182.
125. Colthorpe P., Farr S.J., Taylor G., Smith I.J., Wyatt D. The pharmacokinetics of pulmonary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm. Res. 1992, 9:764-768.
126. Colthorpe P., Farr S.J., Smith I.J., Wyatt D., Taylor G. The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. Pharm. Res. 1995, 12:356-359.
127. Jeffery P.K., Li D. Airway mucosa: secretory cells, mucus and mucin genes. Eur. Respir. J. 1997, 10:1655-1662.
128. Williams O.W., Sharafkhaneh A., Kim V., Dickey B.F., Evans C.M. Airway mucus: from production to secretion. Am. J. Respir. Cell Mol. Biol. 2006, 34:527-536.
129. Lillehoj E.R., Kim K.C. Airway mucus: its components and function. Arch. Pharm. Res. 2002, 25:770-780.
130. Rubin B.K. Physiology of airway mucus clearance. Respir. Care 2002, 47:761-768.
131. Widdicombe J.H., Bastacky S.J., Wu D.X., Lee C.Y. Regulation of depth and composition of airway surface liquid. Eur. Respir. J. 1997, 10:2892-2897.
132. Katsara M., Tselios T., Deraos S., Deraos G., Matsoukas M.T., Lazoura E., Matsoukas J., Apostolopoulos V. Round and round we go: cyclic peptides in disease. Curr. Med. Chem. 2006, 13:2221-2232.
133. von Wartburg A., Traber R. Cyclosporins, Fungal Metabolites with Immunosuppressive Activities. Progress in Medicinal Chemistry 1988, vol. 25:1-34. Elsevier. G.P. E., G.B. W. (Eds.).
134. Magni F., Arcelloni C., Paroni R., Fermo I., Bonini P.A., Del Puppo M., Manzocchi A., Galli Kienle M. Open-chain peptides obtained by acidic hydrolytic cleavage of cyclosporin A. Biol. Mass Spectrom. 1994, 23:514-518.
135. Geisow M.J., D'Arcy Hart P., Young M.R. Temporal changes of lysosome and phagosome pH during phagolysosome formation in macrophages: studies by fluorescence spectroscopy. J. Cell Biol. 1981, 89:645-652.
136. Oliyai R., Safadi M., Meier P.G., Hu M.K., Rich D.H., Stella V.J. Kinetics of acid-catalyzed degradation of cyclosporin A and its analogs in aqueous solution. Int. J. Pept. Protein Res. 1994, 43:239-247.
137. Oliyai R., Stella V.J. Kinetics and mechanism of isomerization of cyclosporin A. Pharm. Res. 1992, 9:617-622.
138. Smith J.M., Hows J.M., Gordon-Smith E.C. Stability of cyclosporin A in human serum. J. Clin. Pathol. 1983, 36:41-43.
139. Hows J.M., Smith J.M. In vitro stability of cyclosporin A. J. Clin. Pathol. 1983, 36:720-721.
140. Michel M.C., Thesing A., Wagner K., Philipp T. Stability of cyclosporin in blood upon shipping-related extended storage. Nephrol. Dial. Transplant. 1995, 10:910-911.
141. McLeod H.L., McGuire T.R., Yee G.C. Stability of cyclosporine in dextrose 5%, NaCl 0.9%, dextrose/amino acid solution, and lipid emulsion. Ann. Pharmacother. 1992, 26:172-175.
142. Ptachcinski R.J., Logue L.W., Burckart G.J., Venkataramanan R. Stability and availability of cyclosporine in 5% dextrose injection or 0.9% sodium chloride injection. Am. J. Hosp. Pharm. 1986, 43:94-97.
143. Ozbay A., Karamperis N., Jorgensen K.A. A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue. Curr. Clin. Pharmacol. 2007, 2:244-248.
144. Copeland K.R., Thliveris J.A., Yatscoff R.W. Toxicity of cyclosporine metabolites. Ther. Drug Monit. 1990, 12:525-532.
145. Maurer G., Lemaire M. Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant. Proc. 1986, 18:25-34.
146. Kolars J.C., Awni W.M., Merion R.M., Watkins P.B. First-pass metabolism of cyclosporin by the gut. Lancet 1991, 338:1488-1490.
147. Wu C.Y., Benet L.Z., Hebert M.F., Gupta S.K., Rowland M., Gomez D.Y., Wacher V.J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 1995, 58:492-497.
148. Krishna D.R., Klotz U. Extrahepatic metabolism of drugs in humans. Clin. Pharmacokinet. 1994, 26:144-160.
149. Pavek P., Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab. 2008, 9:129-143.
150. Bernauer U., Heinrich-Hirsch B., Tonnies M., Peter-Matthias W., Gundert-Remy U. Characterisation of the xenobiotic-metabolizing Cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination. Toxicol. Lett. 2006, 164:278-288.
151. Zhang J.Y., Wang Y., Prakash C. Xenobiotic-metabolizing enzymes in human lung. Curr. Drug Metab. 2006, 7:939-948.
152. Raunio H., Hakkola J., Pelkonen O. Regulation of CYP3A genes in the human respiratory tract. Chem. Biol. Interact. 2005, 151:53-62.
153. Pacifici G.M., Franchi M., Bencini C., Repetti F., Di Lascio N., Muraro G.B. Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica 1988, 18:849-856.
154. Shimada T., Yamazaki H., Mimura M., Wakamiya N., Ueng Y.F., Guengerich F.P., Inui Y. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos. 1996, 24:515-522.
155. Raunio H., Hakkola J., Hukkanen J., Lassila A., Paivarinta K., Pelkonen O., Anttila S., Piipari R., Boobis A., Edwards R.J. Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp. Toxicol. Pathol. 1999, 51:412-417.
156. Anttila S., Hukkanen J., Hakkola J., Stjernvall T., Beaune P., Edwards R.J., Boobis A.R., Pelkonen O., Raunio H. Expression and localization of CYP3A4 and CYP3A5 in human lung. Am. J. Respir. Cell Mol. Biol. 1997, 16:242-249.
157. Utecht K.N., Hiles J.J., Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am. J. Health-Syst. Pharm. 2006, 63:2340-2348.
158. Anglicheau D., Legendre C., Beaune P., Thervet E. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 2007, 8:835-849.
159. Vickers A.E., Jimenez R.M., Spaans M.C., Pflimlin V., Fisher R.L., Brendel K. Human and rat lung biotransformation of cyclosporin A and its derivatives using slices and bronchial epithelial cells. Drug Metab. Dispos. 1997, 25:873-880.
160. Kelly P.A., Wang H., Napoli K.L., Kahan B.D., Strobel H.W. Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur. J. Drug Metab. Pharmacokinet. 1999, 24:321-328.
161. Koseki N., Nakashima A., Nagae Y., Masuda N. Simultaneous quantitative determination of cyclosporine A and its three main metabolites (AM1, AM4N and AM9) in human blood by liquid chromatography/mass spectrometry using a rapid sample processing method. Rapid Commun. Mass Spectrom. 2006, 20:733-740.
162. Zissel G., Ernst M., Rabe K., Papadopoulos T., Magnussen H., Schlaak M., Muller-Quernheim J. Human alveolar epithelial cells type II are capable of regulating T-cell activity. J. Investig. Med. 2000, 48:66-75.
163. Aoki Y., Qiu D., Uyei A., Kao P.N. Human airway epithelial cells express interleukin-2 in vitro. Am. J. Physiol. 1997, 272:L276-L286.
164. Erjefalt J.S., Persson C.G. Airway epithelial repair: breathtakingly quick and multipotentially pathogenic. Thorax 1997, 52:1010-1012.
165. Polito A.J., Proud D. Epithelia cells as regulators of airway inflammation. J. Allergy Clin. Immunol. 1998, 102:714-718.
166. Mills P.R., Davies R.J., Devalia J.L. Airway epithelial cells, cytokines, and pollutants. Am. J. Respir. Crit. Care Med. 1999, 160:S38-S43.
167. King L.S. Surprises from the airway epithelium. Proc. Natl. Acad. Sci. USA 2001, 98:14192-14194.
168. Stick S.M., Holt P.G. The airway epithelium as immune modulator: the LARC ascending. Am. J. Respir. Cell Mol. Biol. 2003, 28:641-644.
169. Message S.D., Johnston S.L. Host defense function of the airway epithelium in health and disease: clinical background. J. Leukoc. Biol. 2004, 75:5-17.
170. Bartlett J.A., Fischer A.J., McCray P.B. Innate immune functions of the airway epithelium. Contrib. Microbiol. 2008, 15:147-163.
171. MacMicking J.D. Recognizing macrophage activation and host defense. Cell Host Microbe 2009, 5:405-407.
172. Martinez-Pomares L., Gordon S. Antigen presentation the macrophage way. Cell 2007, 131:641-643.
173. Lambrecht B.N. Alveolar macrophage in the driver's seat. Immunity 2006, 24:366-368.
174. Reynolds H.Y. Lung inflammation and fibrosis: an alveolar macrophage-centered perspective from the 1970s to 1980s. Am. J. Respir. Crit. Care Med. 2005, 171:98-102.
175. Farver C.F., Raychaudhuri B., Malur A., Drazba J., Maurer J., Tubbs R., Mehta A.C., Schilz R., Thomassen M.J. Increased alveolar macrophage nuclear factor-kappa B activation and macrophage inhibitory protein-1alpha levels in lung transplant patients. Transplantation 2000, 70:1599-1603.
176. Brody A.R. Whither goes the alveolar macrophage? Another small chapter is written on the localized response of this crucial cell. J. Lab. Clin. Med. 1998, 131:391-392.
177. Upham J.W., Strickland D.H., Robinson B.W., Holt P.G. Selective inhibition of T cell proliferation but not expression of effector function by human alveolar macrophages. Thorax 1997, 52:786-795.
178. Upham J.W., Strickland D.H., Bilyk N., Robinson B.W., Holt P.G. Alveolar macrophages from humans and rodents selectively inhibit T-cell proliferation but permit T-cell activation and cytokine secretion. Immunology 1995, 84:142-147.
179. Bilyk N., Holt P.G. Cytokine modulation of the immunosuppressive phenotype of pulmonary alveolar macrophage populations. Immunology 1995, 86:231-237.
180. Power C.K., Burke C.M., Sreenan S., Hurson B., Poulter L.W. T-cell and macrophage subsets in the bronchial wall of clinically healthy subjects. Eur. Respir. J. 1994, 7:437-441.
181. Strickland D.H., Thepen T., Kees U.R., Kraal G., Holt P.G. Regulation of T-cell function in lung tissue by pulmonary alveolar macrophages. Immunology 1993, 80:266-272.
182. Tavora F., Drachenberg C., Iacono A., Burke A.P. Quantitation of T lymphocytes in posttransplant transbronchial biopsies. Hum. Pathol. 2009, 40:505-515.
183. Medoff B.D., Thomas S.Y., Banerji A., Wain J.C., Zhang H., Lilly C.M., Ginns L.C., Luster A.D. Pathogenic T-cell recruitment into the airway in human disease. Ann. NY Acad. Sci. 2005, 1062:220-241.
184. Fliegert F.G., Tschernig T., Pabst R. Comparison of lymphocyte subsets, monocytes, and NK cells in three different lung compartments and peripheral blood in the rat. Exp. Lung Res. 1996, 22:677-690.
185. Duncan S.R., Valentine V., Roglic M., Elias D.J., Pekny K.W., Theodore J., Kono D.H., Theofilopoulos A.N. T cell receptor biases and clonal proliferations among lung transplant recipients with obliterative bronchiolitis. J. Clin. Invest. 1996, 97:2642-2650.
186. Fournier M., Igual J., Groussard O., Mal H., Sleiman C., Duchatelle J.P., Raffy O., Jebrak G., Luzerne-Zedda C., Andreassian B., et al. Mucosal T-lymphocytes in central airways of lung transplant recipients. Am. J. Respir. Crit. Care Med. 1995, 151:1974-1980.
187. Duquesnoy R.J., Trager J.D., Zeevi A. Propagation and characterization of lymphocytes from transplant biopsies. Crit. Rev. Immunol. 1991, 10:455-480.
188. Laurent G.J., McAnulty R.J., Hill M., Chambers R. Escape from the matrix: multiple mechanisms for fibroblast activation in pulmonary fibrosis. Proc. Am. Thorac. Soc. 2008, 5:311-315.
189. Willis B.C., Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293:L525-L534.
190. Laurent G.J., Chambers R.C., Hill M.R., McAnulty R.J. Regulation of matrix turnover: fibroblasts, forces, factors and fibrosis. Biochem. Soc. Trans. 2007, 35:647-651.
191. Willis B.C., duBois R.M., Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc. Am. Thorac. Soc. 2006, 3:377-382.
192. Phan S.H. Fibroblast phenotypes in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2003, 29:S87-S92.
193. Tamm M., Roth M., Malouf M., Chhajed P., Johnson P., Black J., Glanville A. Primary fibroblast cell cultures from transbronchial biopsies of lung transplant recipients. Transplantation 2001, 71:337-339.
194. Tipton D.A., Dabbous M.K. Binding and subcellular distribution of cyclosporine in human fibroblasts. J. Cell. Biochem. 1993, 51:345-352.
195. Tipton D.A., Stricklin G.P., Dabbous M.K. Fibroblast heterogeneity in collagenolytic response to cyclosporine. J. Cell. Biochem. 1991, 46:152-165.
196. Phipps R.P., Penney D.P., Keng P., Quill H., Paxhia A., Derdak S., Felch M.E. Characterization of two major populations of lung fibroblasts: distinguishing morphology and discordant display of Thy 1 and class II MHC. Am. J. Respir. Cell Mol. Biol. 1989, 1:65-74.
197. Tschernig T., de Vries V.C., Debertin A.S., Braun A., Walles T., Traub F., Pabst R. Density of dendritic cells in the human tracheal mucosa is age dependent and site specific. Thorax 2006, 61:986-991.
198. von Garnier C., Filgueira L., Wikstrom M., Smith M., Thomas J.A., Strickland D.H., Holt P.G., Stumbles P.A. Anatomical location determines the distribution and function of dendritic cells and other APCs in the respiratory tract. J. Immunol. 2005, 175:1609-1618.
199. Ciesek S., Ringe B.P., Strassburg C.P., Klempnauer J., Manns M.P., Wedemeyer H., Becker T. Effects of cyclosporine on human dendritic cell subsets. Transplant. Proc. 2005, 37:20-24.
200. Tajima K., Amakawa R., Ito T., Miyaji M., Takebayashi M., Fukuhara S. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology 2003, 108:321-328.
201. Leonard C.T., Soccal P.M., Singer L., Berry G.J., Theodore J., Holt P.G., Doyle R.L., Rosen G.D. Dendritic cells and macrophages in lung allografts: a role in chronic rejection?. Am. J. Respir. Crit. Care Med. 2000, 161:1349-1354.
202. Holt P.G., Stumbles P.A. Characterization of dendritic cell populations in the respiratory tract. J. Aerosol Med. 2000, 13:361-367.
203. Uyama T., Winter J.B., Sakiyama S., Monden Y., Groen G., Prop J. Replacement of dendritic cells in the airways of rat lung allografts. Am. Rev. Respir. Dis. 1993, 148:760-767.
204. Holt P.G. Pulmonary dendritic cell populations. Adv. Exp. Med. Biol. 1993, 329:557-562.
205. Holt P.G., Oliver J., McMenamin C., Schon-Hegrad M.A. Studies on the surface phenotype and functions of dendritic cells in parenchymal lung tissue of the rat. Immunology 1992, 75:582-587.
206. Holt P.G., Schon-Hegrad M.A., McMenamin P.G. Dendritic cells in the respiratory tract. Int. Rev. Immunol. 1990, 6:139-149.
207. Holt P.G., Schon-Hegrad M.A. Localization of T cells, macrophages and dendritic cells in rat respiratory tract tissue: implications for immune function studies. Immunology 1987, 62:349-356.
208. Bradding P. Human lung mast cell heterogeneity. Thorax 2009, 64:278-280.
209. Krishnaswamy G., Ajitawi O., Chi D.S. The human mast cell: an overview. Meth. Mol. Biol. 2006, 315:13-34.
210. Wedemeyer J., Galli S.J. Mast cells and basophils in acquired immunity. Br. Med. Bull. 2000, 56:936-955.
211. Thomson A.W. The effects of cyclosporin A on non-T cell components of the immune system. J. Autoimmun. 1992, 5(Suppl A):167-176.
212. Shanahan F., MacNiven I., Dyck N., Denburg J.A., Bienenstock J., Befus A.D. Human lung mast cells: distribution and abundance of histochemically distinct subpopulations. Int. Arch. Allergy Appl. Immunol. 1987, 83:329-331.
213. Wasserman S.I. The human lung mast cell. Environ. Health Perspect. 1984, 55:259-269.
214. Wasserman S.I. The lung mast cell: its physiology and potential relevance to defense of the lung. Environ. Health Perspect. 1980, 35:153-164.
215. Vanaudenaerde B.M., Meyts I., Vos R., Geudens N., De Wever W., Verbeken E.K., Van Raemdonck D.E., Dupont L.J., Verleden G.M. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur. Respir. J. 2008, 32:832-843.
216. Zheng L., Whitford H.M., Orsida B., Levvey B.J., Bailey M., Walters E.H., Williams T.J., Kotsimbos T., Snell G.I. The dynamics and associations of airway neutrophilia post lung transplantation. Am. J. Transplant. 2006, 6:599-608.
217. Brazil T.J., Dagleish M.P., McGorum B.C., Dixon P.M., Haslett C., Chilvers E.R. Kinetics of pulmonary neutrophil recruitment and clearance in a natural and spontaneously resolving model of airway inflammation. Clin. Exp. Allergy 2005, 35:854-865.
218. Kozower B.D., Kanaan S.A., Tagawa T., Suda T., Grapperhaus K., Daddi N., Crouch E.C., Doerschuk C.M., Patterson G.A. Intramuscular gene transfer of interleukin-10 reduces neutrophil recruitment and ameliorates lung graft ischemia-reperfusion injury. Am. J. Transplant. 2002, 2:837-842.
219. MacNee W. Pulmonary neutrophil kinetics. Clin. Phys. Physiol. Meas. 1990, 11(Suppl A):133-139.
220. Arock M., Schneider E., Boissan M., Tricottet V., Dy M. Differentiation of human basophils: an overview of recent advances and pending questions. J. Leukoc. Biol. 2002, 71:557-564.
221. MacGlashan D., Gauvreau G., Schroeder J.T. Basophils in airway disease. Curr. Allergy Asthma Rep. 2002, 2:126-132.
222. Dvorak A.M. Ultrastructural studies of human basophils and mast cells. J. Histochem. Cytochem. 2005, 53:1043-1070.
223. Min B., Le Gros G., Paul W.E. Basophils: a potential liaison between innate and adaptive immunity. Allergol. Int. 2006, 55:99-104.
224. Harrison C.A., Bastan R., Peirce M.J., Munday M.R., Peachell P.T. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br. J. Pharmacol. 2007, 150:509-518.
225. Sullivan B.M., Locksley R.M. Basophils: a nonredundant contributor to host immunity. Immunity 2009, 30:12-20.
226. Pabst R., Tschernig T. Lymphocytes in the lung: an often neglected cell. Numbers, characterization and compartmentalization. Anat. Embryol. (Berl) 1995, 192:293-299.
227. Holt P.G., Robinson B.W., Reid M., Kees U.R., Warton A., Dawson V.H., Rose A., Schon-Hegrad M., Papadimitriou J.M. Extraction of immune and inflammatory cells from human lung parenchyma: evaluation of an enzymatic digestion procedure. Clin. Exp. Immunol. 1986, 66:188-200.
228. Ermert L., Duncker H.R., Rosseau S., Schutte H., Seeger W. Morphometric analysis of pulmonary intracapillary leukocyte pools in ex vivo-perfused rabbit lungs. Am. J. Physiol. 1994, 267:L64-L70.
229. Doerschuk C.M., Downey G.P., Doherty D.E., English D., Gie R.P., Ohgami M., Worthen G.S., Henson P.M., Hogg J.C. Leukocyte and platelet margination within microvasculature of rabbit lungs. J. Appl. Physiol. 1990, 68:1956-1961.
230. Klemm A., Tschernig T., Ermert L., Althoff A., Merkle M., Gebert A., Ermert M., Seeger W., Pabst R. Blockade of leucocyte function-associated antigen-1 (LFA-1) decreases lymphocyte trapping in the normal pulmonary vasculature: studies in the isolated buffer-perfused rat lung. Clin. Exp. Immunol. 2000, 121:375-383.
231. Szeto W.Y., Krasinskas A.M., Kreisel D., Popma S.H., Rosengard B.R. Donor antigen-presenting cells are important in the development of obliterative airway disease. J. Thorac. Cardiovasc. Surg. 2000, 120:1070-1077.
232. Yu G., Xu X., Vu M.D., Kilpatrick E.D., Li X.C. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J. Exp. Med. 2006, 203:1851-1858.
233. Hasegawa T., Iacono A., Yousem S.A. The significance of bronchus-associated lymphoid tissue in human lung transplantation: is there an association with acute and chronic rejection?. Transplantation 1999, 67:381-385.
234. Thaunat O., Patey N., Caligiuri G., Gautreau C., Mamani-Matsuda M., Mekki Y., Dieu-Nosjean M.C., Eberl G., Ecochard R., Michel J.B., Graff-Dubois S., Nicoletti A. Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J. Immunol. 2010, 185:717-728.
235. Suchin E.J., Langmuir P.B., Palmer E., Sayegh M.H., Wells A.D., Turka L.A. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 2001, 166:973-981.
236. Murphy K., Travers P., Walport M. Janeway's immunobiology. Garland Science 2008, Taylor and Francis group, New York.
237. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 1996, 17:138-146.
238. Romagnani S. T-cell subsets (Th1 versus Th2). Ann. Allergy Asthma Immunol. 2000, 85:9-18. quiz 18, 21.
239. Constant S.L., Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 1997, 15:297-322.
240. Chen Z., O'Shea J.J. Th17 cells: a new fate for differentiating helper T cells. Immunol. Res. 2008, 41:87-102.
241. Traves S.L., Donnelly L.E. Th17 cells in airway diseases. Curr. Mol. Med. 2008, 8:416-426.
242. Afzali B., Lombardi G., Lechler R.I., Lord G.M. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 2007, 148:32-46.
243. Lo A., Burckart G.J. P-glycoprotein and drug therapy in organ transplantation. J. Clin. Pharmacol. 1999, 39:995-1005.
244. Studer S.M., George M.P., Zhu X., Song Y., Valentine V.G., Stoner M.W., Sethi J., Steele C., Duncan S.R. CD28 down-regulation on CD4 T cells is a marker for graft dysfunction in lung transplant recipients. Am. J. Respir. Crit. Care Med. 2008, 178:765-773.
245. Wood K.J., Ushigome H., Karim M., Bushell A., Hori S., Sakaguchi S. Regulatory cells in transplantation. Novartis Found. Symp. 2003, 252:177-188. discussion 188-193, 203-110.
246. Bharat A., Fields R.C., Mohanakumar T. Regulatory T cell-mediated transplantation tolerance. Immunol. Res. 2005, 33:195-212.
247. Yong Z., Chang L., Mei Y.X., Yi L. Role and mechanisms of CD4+CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance. Transpl. Immunol. 2007, 17:120-129.
248. Li B., Greene M.I. Special regulatory T-cell review: FOXP3 biochemistry in regulatory T cells - how diverse signals regulate suppression. Immunology 2008, 123:17-19.
249. Campbell D.J., Ziegler S.F. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat. Rev. Immunol. 2007, 7:305-310.
250. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
251. Zhang G.Y., Hu M., Wang Y.M., Alexander S.I. Foxp3 as a marker of tolerance induction versus rejection. Curr. Opin. Organ Transplant. 2009, 14:40-45.
252. Yamazaki S., Steinman R.M. Dendritic cells as controllers of antigen-specific Foxp3+ regulatory T cells. J. Dermatol. Sci. 2009, 54:69-75.
253. Tran D.Q., Shevach E.M. Therapeutic potential of FOXP3(+) regulatory T cells and their interactions with dendritic cells. Hum. Immunol. 2009, 70:294-299.
254. Coenen J.J., Koenen H.J., van Rijssen E., Hilbrands L.B., Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006, 107:1018-1023.
255. Wang H., Zhao L., Sun Z., Sun L., Zhang B., Zhao Y. A potential side effect of cyclosporin A: inhibition of CD4(+)CD25(+) regulatory T cells in mice. Transplantation 2006, 82:1484-1492.
256. O'Rourke A.M., Mescher M.F. The roles of CD8 in cytotoxic T lymphocyte function. Immunol. Today 1993, 14:183-188.
257. Gregson A.L., Hoji A., Saggar R., Ross D.J., Kubak B.M., Jamieson B.D., Weigt S.S., Lynch J.P., Ardehali A., Belperio J.A., Yang O.O. Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection. Transplantation 2008, 85:1056-1059.
258. West E.E., Lavoie T.L., Orens J.B., Chen E.S., Ye S.Q., Finkelman F.D., Garcia J.G., McDyer J.F. Pluripotent allospecific CD8+ effector T cells traffic to lung in murine obliterative airway disease. Am. J. Respir. Cell Mol. Biol. 2006, 34:108-118.
259. Viola A., Contento R.L., Molon B. T cells and their partners: the chemokine dating agency. Trends Immunol. 2006, 27:421-427.
260. Viola A., Molon B., Contento R.L. Chemokines: coded messages for T-cell missions. Front. Biosci. 2008, 13:6341-6353.
261. Tschernig T., Hoffmann A., Pabst R. Local proliferation contributes to lymphocyte numbers in normal lungs. Exp. Toxicol. Pathol. 2001, 53:187-194.
262. Pabst R., Tschernig T. Lymphocyte dynamics: caution in interpreting BAL numbers. Thorax 1997, 52:1078-1080.
263. Hutter J.A., Stewart S., Higenbottam T., Scott J.P., Wallwork J. Histologic changes in heart-lung transplant recipients during rejection episodes and at routine biopsy. J. Heart Transplant. 1988, 7:440-444.
264. Yousem S.A., Randhawa P., Locker J., Paradis I.L., Dauber J.A., Griffith B.P., Nalesnik M.A. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft. Hum. Pathol. 1989, 20:361-369.
265. Berger R., Meingassner J.G., Knapp W. In vitro effects of cyclosporin A on human B-cell responses. Scand. J. Immunol. 1983, 17:241-249.
266. Muraguchi A., Butler J.L., Kehrl J.H., Falkoff R.J., Fauci A.S. Selective suppression of an early step in human B cell activation by cyclosporin A. J. Exp. Med. 1983, 158:690-702.
267. O'Garra A., Warren D.J., Holman M., Popham A.M., Sanderson C.J., Klaus G.G. Effects of cyclosporine on responses of murine B cells to T cell-derived lymphokines. J. Immunol. 1986, 137:2220-2224.
268. Klaus G.G. Cyclosporine-sensitive and cyclosporine-insensitive modes of B cell stimulation. Transplantation 1988, 46:11S-14S.
269. Renz H., Mazer B.D., Gelfand E.W. Differential inhibition of T and B cell function in IL-4-dependent IgE production by cyclosporin A and methylprednisolone. J. Immunol. 1990, 145:3641-3646.
270. Lun M.T., Cochi S., Fioravanti D., Nazzari C., Raponi G., Mannella E., Di Tommaso G., Mancini C., Filadoro F. Effect of cyclosporin A on B cell maturation and differentiation. Drugs Exp. Clin. Res. 1991, 17:493-500.
271. Wicker L.S., Boltz R.C., Matt V., Nichols E.A., Peterson L.B., Sigal N.H. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur. J. Immunol. 1990, 20:2277-2283.
272. Venkataraman L., Francis D.A., Wang Z., Liu J., Rothstein T.L., Sen R. Cyclosporin-A sensitive induction of NF-AT in murine B cells. Immunity 1994, 1:189-196.
273. Holt P.G., Schon-Hegrad M.A., Phillips M.J., McMenamin P.G. Ia-positive dendritic cells form a tightly meshed network within the human airway epithelium. Clin. Exp. Allergy 1989, 19:597-601.
274. Schon-Hegrad M.A., Oliver J., McMenamin P.G., Holt P.G. Studies on the density, distribution, and surface phenotype of intraepithelial class II major histocompatibility complex antigen (Ia)-bearing dendritic cells (DC) in the conducting airways. J. Exp. Med. 1991, 173:1345-1356.
275. Obregon C., Rothen-Rutishauser B., Gitahi S.K., Gehr P., Nicod L.P. Exovesicles from human activated dendritic cells fuse with resting dendritic cells, allowing them to present alloantigens. Am. J. Pathol. 2006, 169:2127-2136.
276. Montecalvo A., Shufesky W.J., Stolz D.B., Sullivan M.G., Wang Z., Divito S.J., Papworth G.D., Watkins S.C., Robbins P.D., Larregina A.T., Morelli A.E. Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. J. Immunol. 2008, 180:3081-3090.
277. Morelli A.E. The immune regulatory effect of apoptotic cells and exosomes on dendritic cells: its impact on transplantation. Am. J. Transplant. 2006, 6:254-261.
278. Schlichting C.L., Schareck W.D., Kofler S., Weis M. Involvement of dendritic cells in allograft rejection new implications of dendritic cell-endothelial cell interactions. Mini Rev. Med. Chem. 2007, 7:423-428.
279. Ehser S., Chuang J.J., Kleist C., Sandra-Petrescu F., Iancu M., Wang D., Opelz G., Terness P. Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: promises and difficulties. Hum. Immunol. 2008, 69:165-173.
280. Chen T., Guo J., Yang M., Han C., Zhang M., Chen W., Liu Q., Wang J., Cao X. Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression. Blood 2004, 103:413-421.
281. Sauma D., Fierro A., Mora J.R., Lennon-Dumenil A.M., Bono M.R., Rosemblatt M., Morales J. Cyclosporine preconditions dendritic cells during differentiation and reduces IL-2 and IL-12 production following activation: a potential tolerogenic effect. Transplant. Proc. 2003, 35:2515-2517.
282. Brilot F., Strowig T., Munz C. NK cells interactions with dendritic cells shape innate and adaptive immunity. Front. Biosci. 2008, 13:6443-6454.
283. Hsieh C.L., Obara H., Ogura Y., Martinez O.M., Krams S.M. NK cells and transplantation. Transpl. Immunol. 2002, 9:111-114.
284. Lefkowitz M., Kornbluth J., Tomaszewski J.E., Jorkasky D.K. Natural killer-cell activity in cyclosporine-treated renal allograft recipients. J. Clin. Immunol. 1988, 8:121-127.
285. Wai L.E., Fujiki M., Takeda S., Martinez O.M., Krams S.M. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation 2008, 85:145-149.
286. Iacono A.T., Johnson B.A., Grgurich W.F., Youssef J.G., Corcoran T.E., Seiler D.A., Dauber J.H., Smaldone G.C., Zeevi A., Yousem S.A., Fung J.J., Burckart G.J., McCurry K.R., Griffith B.P. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J. Med. 2006, 354:141-150.
287. Drath D.B., Kahan B.D. Alterations in rat pulmonary macrophage function by the immunosuppressive agents cyclosporine, azathioprine, and prednisolone. Transplantation 1983, 35:588-592.
288. Hidalgo H.A., Helmke R.J., German V.F., Mangos J.A. The effects of cyclosporine and dexamethasone on an alveolar macrophage cell line (NR8383). Transplantation 1992, 53:620-623.
289. Drath D.B., Kahan B.D. Phagocytic cell function in response to immunosuppressive therapy. Arch. Surg. 1984, 119:156-160.
290. Holt P.G. Down-regulation of immune responses in the lower respiratory tract: the role of alveolar macrophages. Clin. Exp. Immunol. 1986, 63:261-270.
291. Magnan A., Mege J.L., Reynaud M., Thomas P., Capo C., Garbe L., Meric B., Badier M., Bongrand P., Viard L., et al. Monitoring of alveolar macrophage production of tumor necrosis factor-alpha and interleukin-6 in lung transplant recipients. Marseille and Montreal Lung Transplantation Group. Am. J. Respir. Crit. Care Med. 1994, 150:684-689.
292. Magnan A., Mege J.L., Escallier J.C., Brisse J., Capo C., Reynaud M., Thomas P., Meric B., Garbe L., Badier M., Viard L., Bongrand P., Giudicelli R., Metras D., Fuentes P., Vervloet D., Noirclerc M. Balance between alveolar macrophage IL-6 and TGF-beta in lung-transplant recipients. Marseille and Montreal Lung Transplantation Group. Am. J. Respir. Crit. Care Med. 1996, 153:1431-1436.
293. Selby C., MacNee W. Factors affecting neutrophil transit during acute pulmonary inflammation: minireview. Exp. Lung Res. 1993, 19:407-428.
294. Niven R.W., Lott F.D., Cribbs J.M. Pulmonary absorption of recombinant methionyl human granulocyte colony stimulating factor (r-huG-CSF) after intratracheal instillation to the hamster. Pharm. Res. 1993, 10:1604-1610.
295. Jones H.A., Schofield J.B., Krausz T., Boobis A.R., Haslett C. Pulmonary fibrosis correlates with duration of tissue neutrophil activation. Am. J. Respir. Crit. Care Med. 1998, 158:620-628.
296. Carden D., Xiao F., Moak C., Willis B.H., Robinson-Jackson S., Alexander S. Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial cadherins. Am. J. Physiol. 1998, 275:H385-H392.
297. Hashimoto S., Okayama Y., Shime N., Kimura A., Funakoshi Y., Kawabata K., Ishizaka A., Amaya F. Neutrophil elastase activity in acute lung injury and respiratory distress syndrome. Respirology 2008, 13:581-584.
298. Fujishima S., Morisaki H., Ishizaka A., Kotake Y., Miyaki M., Yoh K., Sekine K., Sasaki J., Tasaka S., Hasegawa N., Kawai Y., Takeda J., Aikawa N. Neutrophil elastase and systemic inflammatory response syndrome in the initiation and development of acute lung injury among critically ill patients. Biomed. Pharmacother. 2008, 62:333-338.
299. Kaynar A.M., Houghton A.M., Lum E.H., Pitt B.R., Shapiro S.D. Neutrophil elastase is needed for neutrophil emigration into lungs in ventilator-induced lung injury. Am. J. Respir. Cell Mol. Biol. 2008, 39:53-60.
300. Mori H., Nagahiro I., Osaragi T., Kotani K., Nakanishi H., Sano Y., Date H., Shimizu N. Addition of a neutrophil elastase inhibitor to the organ flushing solution decreases lung reperfusion injury in rat lung transplantation. Eur. J. Cardiothorac. Surg. 2007, 32:791-795.
301. Kharazmi A., Svenson M., Nielsen H., Birgens H.S. Effect of cyclosporin A on human neutrophil and monocyte function. Scand. J. Immunol. 1985, 21:585-591.
302. Spisani S., Fabbri E., Muccinelli M., Cariani A., Barbin L., Trotta F., Dovigo L. Inhibition of neutrophil responses by cyclosporin A. An insight into molecular mechanisms. Rheumatology (Oxford) 2001, 40:794-800.
303. Halestrap A.P., Connern C.P., Griffiths E.J., Kerr P.M. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury. Mol. Cell. Biochem. 1997, 174:167-172.
304. Suzuki S., Toledo-Pereyra L.H., Rodriguez F.J., Cejalvo D. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation 1993, 55:1265-1272.
305. Kubes P., Hunter J., Granger D.N. Effects of cyclosporin A and FK506 on ischemia/reperfusion-induced neutrophil infiltration in the cat. Dig. Dis. Sci. 1991, 36:1469-1472.
306. Phipps R.P., Borrello M.A., Blieden T.M. Fibroblast heterogeneity in the periodontium and other tissues. J. Periodontal Res. 1997, 32:159-165.
307. Coker R.K., Laurent G.J. Pulmonary fibrosis: cytokines in the balance. Eur. Respir. J. 1998, 11:1218-1221.
308. Boltchi F.E., Rees T.D., Iacopino A.M. Cyclosporine A-induced gingival overgrowth: a comprehensive review. Quintessence Int. 1999, 30:775-783.
309. Montebugnoli L., Bernardi F. Cyclosporin A effects on extra oral connective tissue in heart transplanted patients. J. Int. Acad. Periodontol. 1999, 1:91-94.
310. Ahmed A., Huang L., Raftery A.T., Ahmed A.K., Fahmy H., El Nahas A.M., Haylor J.L. Cyclosporine A sensitizes the kidney to tubulointerstitial fibrosis induced by renal warm ischemia. Transplantation 2004, 77:686-692.
311. Vieira J.M., Noronha I.L., Malheiros D.M., Burdmann E.A. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow. Transplantation 1999, 68:1746-1753.
312. Azzola A., Havryk A., Chhajed P., Hostettler K., Black J., Johnson P., Roth M., Glanville A., Tamm M. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004, 77:275-280.
313. Hostettler K.E., Roth M., Burgess J.K., Johnson P.R., Glanville A.R., Tamm M., Black J.L., Borger P. Cyclosporine A mediates fibroproliferation through epithelial cells. Transplantation 2004, 77:1886-1893.
314. Xu J., Lamouille S., Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009, 19:156-172.
315. Hodge S., Holmes M., Banerjee B., Musk M., Kicic A., Waterer G., Reynolds P.N., Hodge G., Chambers D.C. Posttransplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. Am. J. Transplant. 2009, 9:727-733.
316. Borthwick L.A., Parker S.M., Brougham K.A., Johnson G.E., Gorowiec M.R., Ward C., Lordan J., Corris P., Kirby J.A., Fisher A.J. Epithelial to mesenchymal transition (EMT) and airway remodelling after human lung transplantation. Thorax 2009, 64:770-777.
317. Ward C., Forrest I.A., Murphy D.M., Johnson G.E., Robertson H., Cawston T.E., Fisher A.J., Dark J.H., Lordan J.L., Kirby J.A., Corris P.A. Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax 2005, 60:865-871.
318. Kim K.K., Kugler M.C., Wolters P.J., Robillard L., Galvez M.G., Brumwell A.N., Sheppard D., Chapman H.A. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. USA 2006, 103:13180-13185.
319. McMorrow T., Gaffney M.M., Slattery C., Campbell E., Ryan M.P. Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol. Dial. Transplant. 2005, 20:2215-2225.
320. Copeland J.W., Beaumont B.W., Merrilees M.J., Pilmore H.L. Epithelial-to-mesenchymal transition of human proximal tubular epithelial cells: effects of rapamycin, mycophenolate, cyclosporin, azathioprine, and methylprednisolone. Transplantation 2007, 83:809-814.
321. Knight D.A., Holgate S.T. The airway epithelium: structural and functional properties in health and disease. Respirology 2003, 8:432-446.
322. Rate A., Upham J.W., Bosco A., McKenna K.L., Holt P.G. Airway epithelial cells regulate the functional phenotype of locally differentiating dendritic cells: implications for the pathogenesis of infectious and allergic airway disease. J. Immunol. 2009, 182:72-83.
323. Kato A., Schleimer R.P. Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr. Opin. Immunol. 2007, 19:711-720.
324. Turner J., Jones C.E. Regulation of mucin expression in respiratory diseases. Biochem. Soc. Trans. 2009, 37:877-881.
325. Rogers D.F. The airway goblet cell. Int. J. Biochem. Cell Biol. 2003, 35:1-6.
326. Rogers D.F. Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir. Care 2007, 52:1134-1146. discussion 1146-1139.
327. Komaromy L., Tigyi A. A unique cell type in the lung - the Clara cell (the non-ciliated bronchiolar epithelial cell). Acta Biol. Hung. 1988, 39:17-29.
328. Widdicombe J.G., Pack R.J. The Clara cell. Eur. J. Respir. Dis. 1982, 63:202-220.
329. Whitsett J.A. Surfactant proteins in innate host defense of the lung. Biol. Neonate 2005, 88:175-180.
330. Beisswenger C., Bals R. Antimicrobial peptides in lung inflammation. Chem. Immunol. Allergy 2005, 86:55-71.
331. Grubor B., Meyerholz D.K., Ackermann M.R. Collectins and cationic antimicrobial peptides of the respiratory epithelia. Vet. Pathol. 2006, 43:595-612.
332. Rawlins E.L. Lung epithelial progenitor cells: lessons from development. Proc. Am. Thorac. Soc. 2008, 5:675-681.
333. Snyder J.C., Teisanu R.M., Stripp B.R. Endogenous lung stem cells and contribution to disease. J. Pathol. 2009, 217:254-264.
334. Warburton D., Perin L., Defilippo R., Bellusci S., Shi W., Driscoll B. Stem/progenitor cells in lung development, injury repair, and regeneration. Proc. Am. Thorac. Soc. 2008, 5:703-706.
335. Hammad H., Lambrecht B.N. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat. Rev. Immunol. 2008, 8:193-204.
336. Takizawa H. Airway epithelial cells as regulators of airway inflammation (Review). Int. J. Mol. Med. 1998, 1:367-378.
337. Cerri C., Chimenti D., Conti I., Neri T., Paggiaro P., Celi A. Monocyte/macrophage-derived microparticles up-regulate inflammatory mediator synthesis by human airway epithelial cells. J. Immunol. 2006, 177:1975-1980.
338. Knight D. Epithelium-fibroblast interactions in response to airway inflammation. Immunol. Cell Biol. 2001, 79:160-164.
339. Adamson I.Y., Hedgecock C., Bowden D.H. Epithelial cell-fibroblast interactions in lung injury and repair. Am. J. Pathol. 1990, 137:385-392.
340. Sacco O., Silvestri M., Sabatini F., Sale R., Defilippi A.C., Rossi G.A. Epithelial cells and fibroblasts: structural repair and remodelling in the airways. Paediatr. Respir. Rev. 2004, 5(Suppl A):S35-S40.
341. Evans M.J., Van Winkle L.S., Fanucchi M.V., Plopper C.G. Cellular and molecular characteristics of basal cells in airway epithelium. Exp. Lung Res. 2001, 27:401-415.
342. Erjefalt J.S., Erjefalt I., Sundler F., Persson C.G. In vivo restitution of airway epithelium. Cell Tissue Res. 1995, 281:305-316.
343. Kuo E., Bharat A., Shih J., Street T., Norris J., Liu W., Parks W., Walter M., Patterson G.A., Mohanakumar T. Role of airway epithelial injury in murine orthotopic tracheal allograft rejection. Ann. Thorac. Surg. 2006, 82:1226-1233.
344. Forrest I.A., Murphy D.M., Ward C., Jones D., Johnson G.E., Archer L., Gould F.K., Cawston T.E., Lordan J.L., Corris P.A. Primary airway epithelial cell culture from lung transplant recipients. Eur. Respir. J. 2005, 26:1080-1085.
345. Parker S.M., Goriwiec M.R., Borthwick L.A., Johnson G., Ward C., Lordan J.L., Corris P.A., Saretzki G.C., Fisher A.J. Airway epithelial cell senescence in the lung allograft. Am. J. Transplant. 2008, 8:1544-1549.
346. Waters V., Sokol S., Reddy B., Soong G., Chun J., Prince A. The effect of cyclosporin A on airway cell proinflammatory signaling and pneumonia. Am. J. Respir. Cell Mol. Biol. 2005, 33:138-144.
347. Neuringer I.P., Sloan J., Budd S., Chalermskulrat W., Park R.C., Stonebraker J.R., O'Neal W.K., Aris R.M., Randell S.H. Calcineurin inhibitor effects on growth and phenotype of human airway epithelial cells in vitro. Am. J. Transplant. 2005, 5:2660-2670.
348. Zhang J.G., Walmsley M.W., Moy J.V., Cunningham A.C., Talbot D., Dark J.H., Kirby J.A. Differential effects of cyclosporin A and tacrolimus on the production of TGF-beta: implications for the development of obliterative bronchiolitis after lung transplantation. Transpl. Int. 1998, 11(Suppl 1):S325-S327.
349. Prussin C., Metcalfe D.D. 5. IgE, mast cells, basophils, and eosinophils. J. Allergy Clin. Immunol. 2006, 117:S450-S456.
350. Parra E.R., Kairalla R.A., Ribeiro de Carvalho C.R., Eher E., Capelozzi V.L. Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia. Respiration 2007, 74:159-169.
351. Schroeder J.T. Basophils beyond effector cells of allergic inflammation. Adv. Immunol. 2009, 101:123-161.
352. Ceyhan B.B., Sungur M., Celikel C.A., Celikel T. Effect of inhaled cyclosporin on the rat airway: histologic and bronchoalveolar lavage assessment. Respiration 1998, 65:71-78.
353. Ceyhan B., Sungur M., Celikel C.A., Celikel T. Effect of inhaled ingredients of a commercial cyclosporin A ampoule on airway inflammation. Respiration 1998, 65:89.
354. Gereke M., Grobe L., Prettin S., Kasper M., Deppenmeier S., Gruber A.D., Enelow R.I., Buer J., Bruder D. Phenotypic alterations in type II alveolar epithelial cells in CD4+ T cell mediated lung inflammation. Respir. Res. 2007, 8:47.
355. Gereke M., Jung S., Buer J., Bruder D. Alveolar type II epithelial cells present antigen to CD4(+) T cells and induce Foxp3(+) regulatory T cells. Am. J. Respir. Crit. Care Med. 2009, 179:344-355.
356. Kannan S., Huang H., Seeger D., Audet A., Chen Y., Huang C., Gao H., Li S., Wu M. Alveolar epithelial type II cells activate alveolar macrophages and mitigate P. aeruginosa infection. PLoS ONE 2009, 4:e4891.
357. Mason R.J. Biology of alveolar type II cells. Respirology 2006, 11(Suppl):S12-S15.
358. Aramburu J., Rao A., Klee C.B. Calcineurin: from structure to function. Curr. Top. Cell. Regul. 2000, 36:237-295.
359. Rusnak F., Mertz P. Calcineurin: form and function. Physiol. Rev. 2000, 80:1483-1521.
360. Klee C.B., Krinks M.H. Purification of cyclic 3', 5'-nucleotide phosphodiesterase inhibitory protein by affinity chromatography on activator protein coupled to Sepharose. Biochemistry 1978, 17:120-126.
361. Cohen P. Classification of protein-serine/threonine phosphatases: identification and quantitation in cell extracts. Meth. Enzymol. 1991, 201:389-398.
362. Kung L., Batiuk T.D., Palomo-Pinon S., Noujaim J., Helms L.M., Halloran P.F. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am. J. Transplant. 2001, 1:325-333.
363. Hubbard M.J., Klee C.B. Calmodulin binding by calcineurin. Ligand-induced renaturation of protein immobilized on nitrocellulose. J. Biol. Chem. 1987, 262:15062-15070.
364. Oh-hora M., Rao A. Calcium signaling in lymphocytes. Curr. Opin. Immunol. 2008, 20:250-258.
365. Hemenway C.S., Heitman J. Calcineurin. Structure, function, and inhibition. Cell Biochem. Biophys. 1999, 30:115-151.
366. Crabtree G.R. Calcium, calcineurin, and the control of transcription. J. Biol. Chem. 2001, 276:2313-2316.
367. Stankunas K., Graef I.A., Neilson J.R., Park S.H., Crabtree G.R. Signaling through calcium, calcineurin, and NF-AT in lymphocyte activation and development. Cold Spring Harb. Symp. Quant. Biol. 1999, 64:505-516.
368. Hogan P.G., Chen L., Nardone J., Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 2003, 17:2205-2232.
369. Batiuk T.D., Halloran P.F. The downstream consequences of calcineurin inhibition. Transplant. Proc. 1997, 29:1239-1240.
370. Kapturczak M.H., Meier-Kriesche H.U., Kaplan B. Pharmacology of calcineurin antagonists. Transplant. Proc. 2004, 36:25S-32S.
371. Fruman D.A., Klee C.B., Bierer B.E., Burakoff S.J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc. Natl. Acad. Sci. USA 1992, 89:3686-3690.
372. Batiuk T.D., Kung L., Halloran P.F. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J. Clin. Invest. 1997, 100:1894-1901.
373. Ho S., Clipstone N., Timmermann L., Northrop J., Graef I., Fiorentino D., Nourse J., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 1996, 80:S40-S45.
374. Liu J., Farmer J.D., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66:807-815.
375. Fukudo M., Yano I., Masuda S., Fukatsu S., Katsura T., Ogura Y., Oike F., Takada Y., Tanaka K., Inui K. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin. Pharmacol. Ther. 2005, 78:168-181.
376. Yano I. Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors. Drug Metab. Pharmacokinet. 2008, 23:150-157.
377. Nashan B., Cole E., Levy G., Thervet E. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation 2002, 73:S3-S11.
378. Thervet E., Anglicheau D., Legendre C., Beaune P. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther. Drug Monit. 2008, 30:143-150.
379. Batiuk T.D., Pazderka F., Halloran P.F. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation 1995, 59:1400-1404.
380. Batiuk T.D., Pazderka F., Enns J., DeCastro L., Halloran P.F. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J. Clin. Invest. 1995, 96:1254-1260.
381. Batiuk T.D., Pazderka F., Halloran P.F. How do cells recover from inhibition by cyclosporine?. Transplant. Proc. 1994, 26:2831-2832.
382. Goldberg H., Ling V., Wong P.Y., Skorecki K. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem. Biophys. Res. Commun. 1988, 152:552-558.
383. Fukudo M., Yano I., Masuda S., Okuda M., Inui K. Distinct inhibitory effects of tacrolimus and cyclosporin A on calcineurin phosphatase activity. J. Pharmacol. Exp. Ther. 2005, 312:816-825.
384. Batiuk T.D., Urmson J., Vincent D., Yatscoff R.W., Halloran P.F. Quantitating immunosuppression. Estimating the 50% inhibitory concentration for in vivo cyclosporine in mice. Transplantation 1996, 61:1618-1624.
385. Halloran P.F., Helms L.M., Kung L., Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999, 68:1356-1361.
386. Iacono A.T., Corcoran T.E., Griffith B.P., Grgurich W.F., Smith D.A., Zeevi A., Smaldone G.C., McCurry K.R., Johnson B.A., Dauber J.H. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur. Respir. J. 2004, 23:384-390.
387. Iacono A.T., Keenan R.J., Duncan S.R., Smaldone G.C., Dauber J.H., Paradis I.L., Ohori N.P., Grgurich W.F., Burckart G.J., Zeevi A., Delgado E., O'Riordan T.G., Zendarsky M.M., Yousem S.A., Griffith B.P. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am. J. Respir. Crit. Care Med. 1996, 153:1451-1455.
388. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker, New York. 2 ed.
389. Velazquez M., Haller J., Amundsen T., Schuster D.P. Regional lung water measurements with PET: accuracy, reproducibility, and linearity. J. Nucl. Med. 1991, 32:719-725.
390. Michard F. Bedside assessment of extravascular lung water by dilution methods: temptations and pitfalls. Crit. Care Med. 2007, 35:1186-1192.
391. Matsuda S., Shibasaki F., Takehana K., Mori H., Nishida E., Koyasu S. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep. 2000, 1:428-434.
392. Montero M., Lobaton C.D., Gutierrez-Fernandez S., Moreno A., Alvarez J. Calcineurin-independent inhibition of mitochondrial Ca2+ uptake by cyclosporin A. Br. J. Pharmacol. 2004, 141:263-268.
393. Leshnower B.G., Kanemoto S., Matsubara M., Sakamoto H., Hinmon R., Gorman J.H., Gorman R.C. Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. Ann. Thorac. Surg. 2008, 86:1286-1292.
394. Sharov V.G., Todor A., Khanal S., Imai M., Sabbah H.N. Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J. Mol. Cell. Cardiol. 2007, 42:150-158.
395. Henke W., Nickel E., Jung K. Cyclosporine A inhibits ATP net uptake of rat kidney mitochondria. Biochem. Pharmacol. 1992, 43:1021-1024.
396. Aupetit B., Ghazi A., Blanchouin N., Toury R., Shechter E., Legrand J.C. Impact on energy metabolism of quantitative and functional cyclosporine-induced damage of kidney mitochondria. Biochim. Biophys. Acta 1988, 936:325-331.
397. Attur M.G., Patel R., Thakker G., Vyas P., Levartovsky D., Patel P., Naqvi S., Raza R., Patel K., Abramson D., Bruno G., Abramson S.B., Amin A.R. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm. Res. 2000, 49:20-26.
398. Marone G., Stellato C., Renda A., Genovese A. Anti-inflammatory effects of glucocorticoids and cyclosporin A on human basophils. Eur. J. Clin. Pharmacol. 1993, 45(Suppl 1):S17-S20. discussion S43-14.
399. Stellato C., de Paulis A., Ciccarelli A., Cirillo R., Patella V., Casolaro V., Marone G. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J. Invest. Dermatol. 1992, 98:800-804.
400. Casolaro V., Spadaro G., Patella V., Marone G. In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils. J. Immunol. 1993, 151:5563-5573.
401. Monguilhott Dalmarco E., Frode T.S., Medeiros Y.S. Additional evidence of acute anti-inflammatory effects of cyclosporin A in a murine model of pleurisy. Transpl. Immunol. 2004, 12:151-157.
402. Wiesenberg-Bottcher I., Wanner K., Pignat W. Anti-inflammatory effects of cyclosporin A (CsA) in carragheenan-induced pleurisy in rats. Agents Actions 1990, 29:105-107.
403. Katz A., Coran A.G., Oldham K.T., Guice K.S. Decreased oxidized glutathione with aerosolized cyclosporine delivery. J. Surg. Res. 1993, 54:597-602.
404. Su C.L., Chen C.F., Chiang L.L., Lee C.N., Wang D., Lo S.L., Kao S.J. Cyclosporine, an immunosuppressant, attenuates phorbol-induced lung injury in rats. Transplant. Proc. 2008, 40:2709-2711.
405. Fletcher L.A., Fassett R.G., Richards R.S., Coombes J.S. Cyclosporine A induced changes to plasma and erythrocyte antioxidant defences. Redox Rep. 2005, 10:2-8.
406. Mun K.C. Total antioxidant status and antioxidant enzymes in cyclosporine treated rats. Transplant. Proc. 2000, 32:2007-2008.